Male (%)
|
33 (55)
|
4 (50)
|
8 (62)
|
6 (43)
|
15 (60)
|
Age (years)
|
1.0 [0.6–2.5]
|
1.0 [0.7–1.9]
|
0.8 [0.2–1.0]
|
0.9 [0.5–2.5]
|
2.0 [1.0–3.2]
|
Body weight (kg)
|
8.2 [4.7–11.7]
|
8.1 [5.9–11.6]
|
4.0 [2.8–8.1]
|
8.8 [6.2–11.5]
|
8.8 [4.8–14.3]
|
PB dose (mg/day)
|
40.0 [20.0–60.0]
|
40.0 [31.0–60.0]
|
16.0 [9.8–23.2]
|
50.0 [27.5–80.0]
|
50.0 [19.0–80.0]
|
Number of daily PB doses (times/day)
|
2.0 [2.0–2.0]
|
2.0 [2.0–2.0]
|
2.0 [1.1–2.5]
|
2.0 [1.5–2.0]
|
2.0 [2.0–2.0]
|
PB dose per body weight (mg/kg/time)
|
2.6 [1.9–3.7]
|
2.6 [2.1–4.3]
|
2.0 [1.1–2.5]
|
2.7 [1.9–3.6]
|
2.9 [2.2–4.7]
|
Serum PB concentration (μg/mL)
|
16.0 [11.2–25.0]
|
15.4 [11.1–20.1]
|
15.7 [12.7–18.8]
|
11.4 [10.1–23.7]
|
17.4 [9.9–34.9]
|
ALB (g/dL)
|
4.1 [3.7–4.4]
|
4.2 [3.3–4.6]
|
4.0 [3.5–4.4]
|
4.3 [3.8–4.5]
|
4.0 [3.7–4.4]
|
AST (U/L)
|
35.9 [28.4–53.9]
|
34.9 [21.6–46.5]
|
46.0 [31.5–63.5]
|
35.0 [28.7–50.5]
|
39.0 [30.0–75.9]
|
ALT (U/L)
|
20.8 [15.0–39.8]
|
19.2 [12.5–25.8]
|
29.8 [13.2–35.5]
|
22.6 [16.5–42.6]
|
29.6 [15.7–52.5]
|
LDH (U/L)
|
272.6 [222.4–334.2]
|
264.5 [212.5–312.6]
|
255.0 [243.0–271.5]
|
320.7 [253.4–388.0]
|
277.0 [225.5–367.7]
|
γGTP (U/L)
|
69.9 [28.8–170.9]
|
30.5 [23.5–93.0]
|
65.0 [31.5–289.5]
|
39.5 [27.7–57.5]
|
76.3 [34.0–172.5]
|
BUN (mg/dL)
|
8.9 [5.8–11.9]
|
8.2 [5.2–13.0]
|
9.0 [3.5–9.6]
|
6.1 [5.4–8.5]
|
9.4 [6.3–13.5]
|
Scr (mg/dL)
|
0.2 [0.2–0.3]
|
0.2 [0.2–0.3]
|
0.2 [0.1–0.3]
|
0.2 [0.2–0.3]
|
0.2 [0.1–0.3]
|
Interacting drug use
|
VPA (%)
|
13 (22)
|
0 (0)
|
3 (23)
|
5 (36)
|
5 (20)
|
Amiodarone (%)
|
1 (2)
|
0 (0)
|
1 (8)
|
0 (0)
|
0 (0)
|
Causative disorder *including duplication
|
Fever convulsion (%)
|
11 (18)
|
2 (25)
|
3 (23)
|
2 (14)
|
4 (16)
|
Epilepsy (%)
|
18 (30)
|
2 (25)
|
3 (23)
|
4 (29)
|
9 (36)
|
Acute encephalitis/acute encephalopathy (%)
|
4 (7)
|
1 (13)
|
2 (15)
|
0 (0)
|
1 (4)
|
Intracranial bleeding (%)
|
9 (15)
|
1 (13)
|
1 (8)
|
5 (36)
|
2 (8)
|
Hypoxic-ischemic encephalopathy (%)
|
16 (27)
|
1 (13)
|
7 (54)
|
3 (21)
|
5 (20)
|
Hyperammonemia (%)
|
2 (3)
|
1 (13)
|
0 (0)
|
0 (0)
|
1 (4)
|
Brain tumor (%)
|
4 (7)
|
1 (13)
|
0 (0)
|
2 (14)
|
1 (4)
|
Angiocholitis (%)
|
2 (3)
|
1 (13)
|
0 (0)
|
0 (0)
|
1 (4)
|
Not clear (%)
|
2 (3)
|
0 (0)
|
0 (0)
|
0 (0)
|
2 (8)
|